Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma
- 29 September 2010
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 152 (1) , 113-116
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter StudyJournal of Clinical Oncology, 2009
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie CellulaireJournal of Clinical Oncology, 2008
- Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trialBlood, 2007
- Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomasJournal of Clinical Oncology, 2007
- Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical studyBlood, 2004
- Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. ClassificationAnnals of Oncology, 1997
- Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimenAnnals of Oncology, 1990
- Cyclophosphamide Therapy of Severe Systemic Necrotizing VasculitisNew England Journal of Medicine, 1979